Drugs / iCaspase9-transduced T cells
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT01494103 | Nov 2011 → May 2029 expected | Epstein-Barr virus infection, X-linked lymphoproliferative syndrome, acute lymphoblastic leukemia, acute myeloid leukemia +3 | Baylor College of Medicine | Active not recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | iCaspase9-transduced T cells | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01494103 ↗ |
| Known as | iC9-T cells | “alloreplete haploidentical T cells expressing the inducible caspase 9 suicide gene (iC9-T cells)” PMID 25977584 ↗ May 2015 |
| Modality | Cell therapy | “special T cells in the laboratory that can be given to the patient” NCT01494103 ↗ |
| Route | Intravenous | “The specially selected and treated T cells will be given by vein (IV) once.” NCT01494103 ↗ |